We're also talking about some good news for people living with progressive MS — the extremely positive outcome of the Phase 2 clinical trial for Ibudilast. We'll tell you about a couple of upcoming educational webinars about Ocrevus and primary progressive MS, and Ocrevus and relapsing remitting MS.
We'll update you on the latest news about Phase 2 clinical trials for cannabis-based medications to treat MS, you'll get a heads-up about a very sneaky (and very dangerous) piece of legislation that is potentially devastating to people living with MS in the U.S., and we'll tell you how you can catch an online video of last week's Progress in MS Research: Live Update 2018 presentation in Australia.
We have a lot to talk about! Are you ready for RealTalk MS?
Ibudilast Clinical Trial Shows Unprecedented Slowing in Brain Atrophy in Progressive MS 1:11
Upcoming Ocrevus Educational Webinars 3:17
MMJ Intl Asks FDA to Approve Cannabis-MS Study 4:22
Pre-Existing Conditions Bill is Healthcare Wolf in Sheep's Clothing 5:34
Progress in MS Research Lie Update 2018 11:33
Interview with Dr. Lisa Melton 12:30
If your podcast app doesn't show these links, you'll find them in the show notes at www.RealTalkMS.com
RealTalk MS Episode 51
Hosted By: Jon Strum
Guest: Dr. Lisa Melton
Tags: MS, MultipleSclerosis, MSResearch, MSResearchAustralia, Ibudilast, ClevelandClinic, CleClinicNews, Ocrevus, Cannabis, MMJInternational, PreExistingConditions, Prexxatstake, RealTalkMS